AMRI Selected to Support AstraZeneca in Delivery of COVID-19 Vaccine

Albany Molecular Research, Inc. (AMRI) has signed a supply agreement with AstraZeneca to support the manufacture of AstraZeneca’s COVID-19 vaccine candidate AZD1222, intended to protect against the SARS-CoV-2 novel coronavirus.

On May 21, 2020, AstraZeneca announced it had received more than $1B from the U.S. Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of the COVID-19 vaccine it is developing in cooperation with University of Oxford.

AMRI has been chosen to contribute to the supply of the vaccine candidate through sterile fill/finish of AZD1222 at AMRI’s drug product manufacturing facility in Albuquerque, New Mexico. The COVID-19 vaccine program will take advantage of the facility’s cGMP manufacturing capacity to potentially produce millions of doses of AZD1222 annually. Preparations for this program have begun at the Albuquerque facility.